IBS Fundamental Analysis - IBERSOL SGPS SA

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to IBS. IBS was compared to 61 industry peers in the Hotels, Restaurants & Leisure industry. IBS has an average financial health and profitability rating. IBS is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IBS was profitable.
IBS had a positive operating cash flow in the past year.
IBS had positive earnings in 4 of the past 5 years.
Each year in the past 5 years IBS had a positive operating cash flow.

1.2 Ratios

With a Return On Assets value of 1.91%, IBS is not doing good in the industry: 62.30% of the companies in the same industry are doing better.
IBS has a Return On Equity of 4.21%. This is comparable to the rest of the industry: IBS outperforms 57.38% of its industry peers.
With a Return On Invested Capital value of 4.53%, IBS perfoms like the industry average, outperforming 40.98% of the companies in the same industry.
IBS had an Average Return On Invested Capital over the past 3 years of 3.32%. This is significantly below the industry average of 12.33%.
The 3 year average ROIC (3.32%) for IBS is below the current ROIC(4.53%), indicating increased profibility in the last year.

		Industry Rank	Sector Rank
ROA	1.91%
ROE	4.21%
ROIC	4.53%

ROA(3y)9.49%

ROA(5y)5.17%

ROE(3y)16.68%

ROE(5y)5.68%

ROIC(3y)3.32%

ROIC(5y)N/A

1.3 Margins

IBS has a worse Profit Margin (2.56%) than 60.66% of its industry peers.
In the last couple of years the Profit Margin of IBS has declined.
IBS has a Operating Margin (5.83%) which is in line with its industry peers.
IBS's Operating Margin has declined in the last couple of years.
IBS's Gross Margin of 52.62% is in line compared to the rest of the industry. IBS outperforms 55.74% of its industry peers.
IBS's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	5.83%
PM (TTM)	2.56%
GM	52.62%

OM growth 3Y-40.02%

OM growth 5Y-6.76%

PM growth 3Y-42.54%

PM growth 5Y-4.22%

GM growth 3Y-0.29%

GM growth 5Y-0.28%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IBS is destroying value.
Compared to 1 year ago, IBS has less shares outstanding
Compared to 5 years ago, IBS has more shares outstanding
Compared to 1 year ago, IBS has a worse debt to assets ratio.

2.2 Solvency

IBS has an Altman-Z score of 2.09. This is not the best score and indicates that IBS is in the grey zone with still only limited risk for bankruptcy at the moment.
IBS has a Altman-Z score of 2.09. This is comparable to the rest of the industry: IBS outperforms 59.02% of its industry peers.
The Debt to FCF ratio of IBS is 3.47, which is a good value as it means it would take IBS, 3.47 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 3.47, IBS is doing good in the industry, outperforming 72.13% of the companies in the same industry.
A Debt/Equity ratio of 0.66 indicates that IBS is somewhat dependend on debt financing.
IBS has a better Debt to Equity ratio (0.66) than 75.41% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.66
Debt/FCF	3.47
Altman-Z	2.09

ROIC/WACC0.73

WACC6.22%

2.3 Liquidity

IBS has a Current Ratio of 1.02. This is a normal value and indicates that IBS is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of IBS (1.02) is better than 63.93% of its industry peers.
A Quick Ratio of 0.92 indicates that IBS may have some problems paying its short term obligations.
IBS's Quick ratio of 0.92 is in line compared to the rest of the industry. IBS outperforms 59.02% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.02
Quick Ratio	0.92

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IBS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.66%.
Measured over the past years, IBS shows a decrease in Earnings Per Share. The EPS has been decreasing by -8.23% on average per year.
IBS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.02%.
The Revenue has been decreasing by -0.46% on average over the past years.

EPS 1Y (TTM)-16.66%

EPS 3Y-29.2%

EPS 5Y-8.23%

EPS Q2Q%83.33%

Revenue 1Y (TTM)15.02%

Revenue growth 3Y32.48%

Revenue growth 5Y-0.46%

Sales Q2Q%7.53%

3.2 Future

Based on estimates for the next years, IBS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.57% on average per year.
The Revenue is expected to grow by 7.42% on average over the next years.

EPS Next Y-25.98%

EPS Next 2Y4.99%

EPS Next 3Y10.92%

EPS Next 5Y17.57%

Revenue Next Year15.95%

Revenue Next 2Y10.49%

Revenue Next 3Y8.64%

Revenue Next 5Y7.42%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 29.85 indicates a quite expensive valuation of IBS.
IBS's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of IBS to the average of the S&P500 Index (27.47), we can say IBS is valued inline with the index average.
IBS is valuated quite expensively with a Price/Forward Earnings ratio of 28.71.
The rest of the industry has a similar Price/Forward Earnings ratio as IBS.
IBS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.26.

		Industry Rank	Sector Rank
PE	29.85
Fwd PE	28.71

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, IBS is valued cheaper than 86.89% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	5.09
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y4.99%

EPS Next 3Y10.92%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IBS has a Yearly Dividend Yield of 7.07%, which is a nice return.
Compared to an average industry Dividend Yield of 1.29, IBS pays a better dividend. On top of this IBS pays more dividend than 100.00% of the companies listed in the same industry.
IBS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.89.

		Industry Rank	Sector Rank
Dividend Yield	7.07%

5.2 History

On average, the dividend of IBS grows each year by 48.65%, which is quite nice.

Dividend Growth(5Y)48.65%

Div Incr Years0

Div Non Decr Years0

5.3 Sustainability

IBS pays out 213.50% of its income as dividend. This is not a sustainable payout ratio.
IBS's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.

DP213.5%

EPS Next 2Y4.99%

EPS Next 3Y10.92%

More info and screens

Find the best dividend stocks

Show peers with best dividend

IBERSOL SGPS SA

ELI:IBS (1/16/2026, 7:00:00 PM)

10.15

+0.23 (+2.32%)

Chartmill FA Rating

GICS SectorConsumer Discretionary

GICS IndustryGroupConsumer Services

GICS IndustryHotels, Restaurants & Leisure

Earnings (Last)11-27 2025-11-27/amc

Earnings (Next)04-27 2026-04-27/amc

Inst Owners21.87%

Inst Owner ChangeN/A

Ins Owners0.03%

Ins Owner ChangeN/A

Market Cap421.33M

Revenue(TTM)522.73M

Net Income(TTM)13.37M

Analysts83.33

Price Target11.92 (17.44%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	7.07%

Yearly Dividend0.49

Dividend Growth(5Y)48.65%

DP213.5%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-2.11%

Min Revenue beat(2)-3.41%

Max Revenue beat(2)-0.81%

Revenue beat(4)2

Avg Revenue beat(4)4.87%

Min Revenue beat(4)-3.41%

Max Revenue beat(4)12.41%

Revenue beat(8)6

Avg Revenue beat(8)5.92%

Revenue beat(12)8

Avg Revenue beat(12)5.42%

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0.86%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)-11.32%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0.48%

Valuation

		Industry Rank	Sector Rank
PE	29.85
Fwd PE	28.71
P/S	0.81
P/FCF	5.09
P/OCF	3.27
P/B	1.33
P/tB	1.92
EV/EBITDA	N/A

EPS(TTM)0.34

EY3.35%

EPS(NY)0.35

Fwd EY3.48%

FCF(TTM)1.99

FCFY19.65%

OCF(TTM)3.1

OCFY30.54%

SpS12.59

BVpS7.64

TBVpS5.28

PEG (NY)N/A

PEG (5Y)N/A

Graham Number7.65

Profitability

		Industry Rank	Sector Rank
ROA	1.91%
ROE	4.21%
ROCE	5.74%
ROIC	4.53%
ROICexc	5.96%
ROICexgc	7.87%
OM	5.83%
PM (TTM)	2.56%
GM	52.62%
FCFM	15.84%

ROA(3y)9.49%

ROA(5y)5.17%

ROE(3y)16.68%

ROE(5y)5.68%

ROIC(3y)3.32%

ROIC(5y)N/A

ROICexc(3y)5.24%

ROICexc(5y)N/A

ROICexgc(3y)7.05%

ROICexgc(5y)N/A

ROCE(3y)4.21%

ROCE(5y)N/A

ROICexgc growth 3Y-24.94%

ROICexgc growth 5Y-3.32%

ROICexc growth 3Y-22.88%

ROICexc growth 5Y-3.24%

OM growth 3Y-40.02%

OM growth 5Y-6.76%

PM growth 3Y-42.54%

PM growth 5Y-4.22%

GM growth 3Y-0.29%

GM growth 5Y-0.28%

F-Score7

Asset Turnover0.75

Health

		Industry Rank	Sector Rank
Debt/Equity	0.66
Debt/FCF	3.47
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	8.77%
Interest Coverage	250
Cash Conversion	N/A
Profit Quality	619.36%
Current Ratio	1.02
Quick Ratio	0.92
Altman-Z	2.09

F-Score7

WACC6.22%

ROIC/WACC0.73

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)9.76%

Cap/Sales(5y)11.65%

Profit Quality(3y)200.89%

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-16.66%

EPS 3Y-29.2%

EPS 5Y-8.23%

EPS Q2Q%83.33%

EPS Next Y-25.98%

EPS Next 2Y4.99%

EPS Next 3Y10.92%

EPS Next 5Y17.57%

Revenue 1Y (TTM)15.02%

Revenue growth 3Y32.48%

Revenue growth 5Y-0.46%

Sales Q2Q%7.53%

Revenue Next Year15.95%

Revenue Next 2Y10.49%

Revenue Next 3Y8.64%

Revenue Next 5Y7.42%

EBIT growth 1Y34.45%

EBIT growth 3Y-20.54%

EBIT growth 5Y-7.19%

EBIT Next Year455.28%

EBIT Next 3Y83.41%

EBIT Next 5Y61.42%

FCF growth 1Y88.1%

FCF growth 3Y-0.14%

FCF growth 5Y-9.32%

OCF growth 1Y61.81%

OCF growth 3Y1.82%

OCF growth 5Y-6.35%

IBERSOL SGPS SA / IBS.LS FAQ

What is the ChartMill fundamental rating of IBERSOL SGPS SA (IBS.LS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to IBS.LS.

Can you provide the valuation status for IBERSOL SGPS SA?

ChartMill assigns a valuation rating of 3 / 10 to IBERSOL SGPS SA (IBS.LS). This can be considered as Overvalued.

Can you provide the profitability details for IBERSOL SGPS SA?

IBERSOL SGPS SA (IBS.LS) has a profitability rating of 4 / 10.

What is the financial health of IBERSOL SGPS SA (IBS.LS) stock?

The financial health rating of IBERSOL SGPS SA (IBS.LS) is 4 / 10.

Can you provide the dividend sustainability for IBS stock?

The dividend rating of IBERSOL SGPS SA (IBS.LS) is 6 / 10 and the dividend payout ratio is 213.5%.

IBERSOL SGPS SA (IBS.LS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens

IBERSOL SGPS SA / IBS.LS FAQ

What is the ChartMill fundamental rating of IBERSOL SGPS SA (IBS.LS) stock?

Can you provide the valuation status for IBERSOL SGPS SA?

Can you provide the profitability details for IBERSOL SGPS SA?

What is the financial health of IBERSOL SGPS SA (IBS.LS) stock?

Can you provide the dividend sustainability for IBS stock?